Shire Overview

  • Founded
  • 1986
Founded
  • Status
  • Acquired/​Merged
  • Employees
  • 23,044
Employees
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $58.2B
Latest Deal Amount

Shire General Information

Description

Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Contact Information

Website
www.shire.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Acquirer
Takeda Pharmaceutical Company
Primary Office
  • Block 2 & 3 Miesian Plaza
  • 50-58 Baggot Street Lower
  • Dublin 2
  • Ireland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Shire Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 08-Jan-2019 $58.2B 00000 000.00 Completed Profitable
4. Merger/Acquisition 20-Oct-2014 0000 0000 Cancelled Profitable
3. PIPE 20-Feb-2007 00000 00000 Completed Profitable
2. IPO 15-Feb-1996 Completed Profitable
1. Early Stage VC Completed Profitable
To view Shire’s complete valuation and funding history, request access »

Shire Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, i
Pharmaceuticals
Dublin, Ireland
23,044 As of 2017
00000
00.00 0000-00-00
000000&0 00000

000

. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo c
0000000000000
Brussels, Belgium
0000 As of 0000
00000
000000 - 000 00000

0000000

. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla paria
0000000000000
Allschwil, Switzerland
0000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Shire Competitors (19)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
UCB Corporation Brussels, Belgium 0000 00000 000000 - 000 00000
0000000 0000000000 Corporate Backed or Acquired Allschwil, Switzerland 0000 00.000 00000000 00.000
0000000 000000 000 Formerly VC-backed Stockholm, Sweden 0000 000.00 000000000000
000 000000 Corporate Backed or Acquired Rockland, MA 0000
0000 0000000 Corporation Bagsvaerd, Denmark 00000 000000000
You’re viewing 5 of 19 competitors. Get the full list »

Shire Patents

  • 1,487

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 39

    Granted

  • 5

    Pending

  • 000

    Expiring in next 12 mo

Shire Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210332383-A1 Adeno associated virus vectors for the treatment of hunter disease Pending 10-Dec-2019 0000000000
EP-3810652-A1 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia Pending 22-Jun-2018 00000000000
US-20210261672-A1 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia Pending 22-Jun-2018 00000000000
JP-2021508322-A Purified arylsulfatase a and its compositions Pending 19-Dec-2017 0000000000
AU-2018393045-A1 Purified arylsulfatase a and compositons thereof Pending 19-Dec-2017 A61K38/465
To view Shire’s complete patent history, request access »

Shire Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Shire Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
HealthCare Ventures Venture Capital Minority 000 0000 000000 0
Permira PE/Buyout Minority 000 0000 000000 0
SV Health Investors Venture Capital Minority 000 0000 000000 0
To view Shire’s complete investors history, request access »

Shire Investments & Acquisitions (52)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000000 06-Sep-2018 0000000000 Laboratory Services (Healthcare)
00000 0000000 04-Jun-2018 00000 0000 000.00 Drug Discovery
0000 00000000 22-Dec-2017 00000 0000 000.00 Drug Delivery
000000 000000 30-Jun-2017 0000000000 Pharmaceuticals
OncoResponse 23-Mar-2017 Early Stage VC 000.00 Drug Discovery
You’re viewing 5 of 52 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Shire Subsidiaries (3)

Company Name Industry Location Founded
Shire Strategic Investment Group Corporate Venture Capital Wayne, PA 2011
0000000000 Laboratory Services (Healthcare) Herisau, Switzerland 0000
000 00000 00000000 Pharmaceuticals Radford, VA 0000
To view Shire’s complete subsidiaries history, request access »

Shire Exits (9)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000 000000000000 22-Dec-2017 00000 00000 00 000.00 Completed
  • 16 buyers
000000 02-Jun-2016 0000 000.00 Completed
  • 2 buyers
000000000 000 30-Jul-2015 00000 00000 00 000.00 Completed
  • 14 buyers
0000000 000000000 01-Jun-2015 00000 0000000 Completed
  • 3 buyers
ArmaGen 01-Jul-2014 Later Stage VC 0000 Completed
You’re viewing 5 of 9 exits. Get the full list »